Pulp Capping in Primary Molars Using TheraCal (LC)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-01

Study Completion Date

2021-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized clinical trial that aims to evaluate clinical and radiographic success rates of indirect pulp capping and direct pulp capping in primary molars with reversible pulpitis using a light-cured tri-calcium silicate base material (TheraCal (LC)).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Conservative Pulp Therapy of Primary Molars Using TheraCAL

NCT04167943

Reversible Pulpitis

COMPLETED PHASE3

Clinical and Radiographic Evaluation of Indirect Pulp Capping in Primary and Permanent Teeth With Different Materials

NCT03606681

Dental Pulp Capping

COMPLETED NA

Light Cured Resin Modified Calcium Silicate Versus Light Cured Calcium Hydroxide in Indirect Pulp Treatment of Primary Molars

NCT03791255

Deep Carious Lesion Indirect Pulp Treatment

UNKNOWN PHASE4

Antibacterial Effect of Light-activated Calcium Silicate Versus Light-activated Calcium Hydroxide

NCT03214770

Dental Caries Extending Into Dentin

UNKNOWN PHASE1

Comparison of Hyaluronic Acid, TheraCal, and Mineral Trioxide Aggregate as Pulpotomy Agents in Primary Molars

NCT07168811

Pulpotomies Primary Teeth Pulp Disease, Dental

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participating primary molars will be randomly allocated to one of the following groups: Indirect pulp capping group or Direct pulp capping group. A light-cured tri-calcium silicate base material (TheraCal (LC) ) will be used in the two groups as a dressing material. Patients will be recruited from the outpatient clinic of the pediatric dentistry department, Faculty of Dentistry Ain Shams University. The participant will be recalled for follow-up assessments at 3, 6,9, and 12 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Deep Caries Indirect Pulp Capping Direct Pulp Capping Reversible Pulpitis Decayed Teeth Vital Pulp Therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Simple parallel randomization was performed by using computerized random numbers

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

The participants and the outcome assessor were blinded. The primary investigator blinding was impossible

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Indirect Pulp Capping

TheraCal (LC) will be applied to affected dentin after excavation of infected dentin

Group Type EXPERIMENTAL

Light cured tri-calcium silicate base material

Intervention Type DRUG

TheraCal (LC) (BISCO Inc., Schamburg, IL, USA) was introduced in (2011), are available commercially as flowable cement applicable via syringe

Direct Pulp Capping

TheraCal (LC) will be applied to pinpoint pulp exposures (less than 1mm ) in vital pulps surrounded by sound dentin.

Group Type EXPERIMENTAL

Light cured tri-calcium silicate base material

Intervention Type DRUG

TheraCal (LC) (BISCO Inc., Schamburg, IL, USA) was introduced in (2011), are available commercially as flowable cement applicable via syringe

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Light cured tri-calcium silicate base material

TheraCal (LC) (BISCO Inc., Schamburg, IL, USA) was introduced in (2011), are available commercially as flowable cement applicable via syringe

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TheraCal (LC)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age: 4-7 years.
2. Free medical history.
3. Complete physical and mental health.
4. Patient cooperation
5. restorable mandibular primary molars

Exclusion Criteria

1. Clinical symptoms or irreversible pulpitis as (spontaneous pain, throbbing pain)
2. Soft tissue swelling, draining fistula or sinus tracts.
3. Tenderness to percussion.
4. Pathological Tooth mobility.
5. Widening of periodontal membrane space

Minimum Eligible Age

4 Years

Maximum Eligible Age

7 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes